Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Observation after surgery for low grade glioma: long-term outcome in the light of the 2016 WHO classification.

Jansen E, Hamisch C, Ruess D, Heiland DH, Goldbrunner R, Ruge MI, Schnell O, Grau SJ.

J Neurooncol. 2019 Oct 16. doi: 10.1007/s11060-019-03316-7. [Epub ahead of print]

PMID:
31621043
2.

Astrogliosis Releases Pro-Oncogenic Chitinase 3-Like 1 Causing MAPK Signaling in Glioblastoma.

Wurm J, Behringer SP, Ravi VM, Joseph K, Neidert N, Maier JP, Doria-Medina R, Follo M, Delev D, Pfeifer D, Beck J, Sankowski R, Schnell O, Heiland DH.

Cancers (Basel). 2019 Sep 26;11(10). pii: E1437. doi: 10.3390/cancers11101437.

3.

Budget Impact of Improved Diabetes Management by Utilization of Glucose Meters With a Color-Range Indicator-Comparison of Five European Healthcare Systems.

Fritzen K, Basinska K, Stautner C, Braun KF, Rubio-Almanza M, Nicolucci A, Kennon B, Vergès B, Hosny Y, Schnell O.

J Diabetes Sci Technol. 2019 Aug 6:1932296819864665. doi: 10.1177/1932296819864665. [Epub ahead of print]

PMID:
31387385
4.

Survival and Prognostic Predictors of Anaplastic Meningiomas.

Masalha W, Heiland DH, Delev D, Fennell JT, Franco P, Scheiwe C, Mercas BI, Mader I, Schnell O, Grauvogel J.

World Neurosurg. 2019 Jul 26. pii: S1878-8750(19)32054-6. doi: 10.1016/j.wneu.2019.07.148. [Epub ahead of print]

PMID:
31356972
6.

Human organotypic brain slice culture: a novel framework for environmental research in neuro-oncology.

Ravi VM, Joseph K, Wurm J, Behringer S, Garrelfs N, d'Errico P, Naseri Y, Franco P, Meyer-Luehmann M, Sankowski R, Shah MJ, Mader I, Delev D, Follo M, Beck J, Schnell O, Hofmann UG, Heiland DH.

Life Sci Alliance. 2019 Jun 27;2(4). pii: e201900305. doi: 10.26508/lsa.201900305. Print 2019 Aug.

7.

Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma.

Henrik Heiland D, Ravi VM, Behringer SP, Frenking JH, Wurm J, Joseph K, Garrelfs NWC, Strähle J, Heynckes S, Grauvogel J, Franco P, Mader I, Schneider M, Potthoff AL, Delev D, Hofmann UG, Fung C, Beck J, Sankowski R, Prinz M, Schnell O.

Nat Commun. 2019 Jun 11;10(1):2541. doi: 10.1038/s41467-019-10493-6.

8.

Pan-European Economic Analysis to Identify Cost Savings for the Health Care Systems as a Result of Integrating Glucose Monitoring Based Telemedical Approaches Into Diabetes Management.

Fritzen K, Basinska K, Rubio-Almanza M, Nicolucci A, Kennon B, Vergès B, Zakrzewska K, Schnell O.

J Diabetes Sci Technol. 2019 Mar 27:1932296819835172. doi: 10.1177/1932296819835172. [Epub ahead of print]

PMID:
30917691
9.

Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.

Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, Skrha J, Valensi P, Ceriello A.

Cardiovasc Diabetol. 2019 Mar 11;18(1):30. doi: 10.1186/s12933-019-0822-4.

10.

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society.

Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.

PMID:
30782343
11.

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.

Heynckes S, Daka K, Franco P, Gaebelein A, Frenking JH, Doria-Medina R, Mader I, Delev D, Schnell O, Heiland DH.

BMC Cancer. 2019 Feb 1;19(1):117. doi: 10.1186/s12885-019-5308-y.

12.

PDM-ProValue meets cardiovascular outcome trials in diabetes.

Fritzen K, Schnell O.

Cardiovasc Diabetol. 2019 Jan 28;18(1):10. doi: 10.1186/s12933-019-0815-3.

13.

Response to "Premature and Incomplete Overview of Health Technology Assessments for Flash Glucose Monitoring Leads to Misleading Conclusions".

Schnell O.

J Diabetes Sci Technol. 2019 May;13(3):603-604. doi: 10.1177/1932296818822512. Epub 2018 Dec 31. No abstract available.

PMID:
30595052
14.

Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system.

Delev D, Heiland DH, Franco P, Reinacher P, Mader I, Staszewski O, Lassmann S, Grau S, Schnell O.

J Neurooncol. 2019 Jan;141(1):223-233. doi: 10.1007/s11060-018-03030-w. Epub 2018 Nov 22.

PMID:
30467813
15.

Correction to: One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?

Heiland DH, Haaker G, Watzlawick R, Delev D, Masalha W, Franco P, Machein M, Staszewski O, Oelhke O, Nicolay NH, Schnell O.

J Neurooncol. 2018 Nov;140(2):393. doi: 10.1007/s11060-018-2994-2.

PMID:
30203165
16.

Health Technology Assessments for Flash Glucose Monitoring and How to Use Them in Everyday Clinical Practice.

Stueve M, Schnell O.

J Diabetes Sci Technol. 2019 May;13(3):584-591. doi: 10.1177/1932296818794668. Epub 2018 Aug 22.

17.

One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?

Heiland DH, Haaker G, Watzlawick R, Delev D, Masalha W, Franco P, Machein M, Staszewski O, Oelhke O, Nicolay NH, Schnell O.

J Neurooncol. 2018 Nov;140(2):385-391. doi: 10.1007/s11060-018-2964-8. Epub 2018 Aug 3. Erratum in: J Neurooncol. 2018 Sep 10;:.

PMID:
30076585
18.

Modeling of Diabetes and Its Clinical Impact.

Fritzen K, Heinemann L, Schnell O.

J Diabetes Sci Technol. 2018 Sep;12(5):976-984. doi: 10.1177/1932296818785642. Epub 2018 Jul 13. Review.

19.

MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results.

Schnell O, Albrecht V, Pfirrmann D, Eigenbrod S, Krebs B, Romagna A, Siller S, Giese A, Tonn JC, Schichor C.

Med Oncol. 2018 Jun 7;35(7):103. doi: 10.1007/s12032-018-1162-z.

PMID:
29882028
20.

MR-spectroscopic imaging of glial tumors in the spotlight of the 2016 WHO classification.

Diamandis E, Gabriel CPS, Würtemberger U, Guggenberger K, Urbach H, Staszewski O, Lassmann S, Schnell O, Grauvogel J, Mader I, Heiland DH.

J Neurooncol. 2018 Sep;139(2):431-440. doi: 10.1007/s11060-018-2881-x. Epub 2018 Apr 27.

PMID:
29704080
21.

Implementation of HbA1c Point of Care Testing in 3 German Medical Practices: Impact on Workflow and Physician, Staff, and Patient Satisfaction.

Patzer KH, Ardjomand P, Göhring K, Klempt G, Patzelt A, Redzich M, Zebrowski M, Emmerich S, Schnell O.

J Diabetes Sci Technol. 2018 May;12(3):687-694. doi: 10.1177/1932296818759690. Epub 2018 Mar 13.

22.

Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (PROTECT study).

Ziegler D, Landgraf R, Lobmann R, Reiners K, Rett K, Schnell O, Strom A.

Diabetes Res Clin Pract. 2018 May;139:147-154. doi: 10.1016/j.diabres.2018.02.043. Epub 2018 Mar 6.

PMID:
29518491
23.

Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.

Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Lalic K, Skrha J, Valensi P, Ceriello A.

Cardiovasc Diabetol. 2018 Feb 19;17(1):30. doi: 10.1186/s12933-018-0667-2.

24.

Improvement of Metabolic Control and Diabetes Management in Insulin-Treated Patients Results in Substantial Cost Savings for the German Health System.

Fritzen K, Gutschek B, Coucke B, Zakrzewska K, Hummel M, Schnell O.

J Diabetes Sci Technol. 2018 Sep;12(5):1002-1006. doi: 10.1177/1932296818758104. Epub 2018 Feb 13.

25.
26.

Microenvironment-Derived Regulation of HIF Signaling Drives Transcriptional Heterogeneity in Glioblastoma Multiforme.

Heiland DH, Gaebelein A, Börries M, Wörner J, Pompe N, Franco P, Heynckes S, Bartholomae M, hAilín DÓ, Carro MS, Prinz M, Weber S, Mader I, Delev D, Schnell O.

Mol Cancer Res. 2018 Apr;16(4):655-668. doi: 10.1158/1541-7786.MCR-17-0680. Epub 2018 Jan 12.

27.

Correction to: Updates on cardiovascular outcome trials in diabetes.

Schnell O, Rydén L, Standl E, Ceriello A; D&CVD EASD Study Group.

Cardiovasc Diabetol. 2017 Nov 15;16(1):150. doi: 10.1186/s12933-017-0633-4.

28.

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U.

Neuro Oncol. 2018 Jun 18;20(7):975-985. doi: 10.1093/neuonc/nox204.

29.

Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme.

Heynckes S, Gaebelein A, Haaker G, Grauvogel J, Franco P, Mader I, Carro MS, Prinz M, Delev D, Schnell O, Heiland DH.

Oncotarget. 2017 Jun 28;8(43):74170-74177. doi: 10.18632/oncotarget.18819. eCollection 2017 Sep 26.

30.

Atypical meningioma: progression-free survival in 161 cases treated at our institution with surgery versus surgery and radiotherapy.

Masalha W, Heiland DH, Franco P, Delev D, Haaker JG, Schnell O, Scheiwe C, Grauvogel J.

J Neurooncol. 2018 Jan;136(1):147-154. doi: 10.1007/s11060-017-2634-2. Epub 2017 Oct 28.

PMID:
29081038
31.

Correction to: Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group.

Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, Valensi P, Rahelic D, Ceriello A.

Cardiovasc Diabetol. 2017 Oct 18;16(1):135. doi: 10.1186/s12933-017-0616-5.

32.

Updates on cardiovascular outcome trials in diabetes.

Schnell O, Rydén L, Standl E, Ceriello A; D&CVD EASD Study Group.

Cardiovasc Diabetol. 2017 Oct 11;16(1):128. doi: 10.1186/s12933-017-0610-y. Review. Erratum in: Cardiovasc Diabetol. 2017 Nov 15;16(1):150.

33.

A New Optimized Percutaneous Access System for CIPII.

Garcia-Verdugo R, Erbach M, Schnell O.

J Diabetes Sci Technol. 2017 Jul;11(4):814-821. doi: 10.1177/1932296817694913. Epub 2017 Mar 1.

34.

The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA1c in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV: A Survey From the European Society of Cardiology.

Shahim B, De Bacquer D, De Backer G, Gyberg V, Kotseva K, Mellbin L, Schnell O, Tuomilehto J, Wood D, Rydén L.

Diabetes Care. 2017 Sep;40(9):1233-1240. doi: 10.2337/dc17-0245. Epub 2017 Jun 21.

35.

Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting.

Schnell O, Barnard K, Bergenstal R, Bosi E, Garg S, Guerci B, Haak T, Hirsch IB, Ji L, Joshi SR, Kamp M, Laffel L, Mathieu C, Polonsky WH, Snoek F, Home P.

Diabetes Technol Ther. 2017 Jul;19(7):391-399. doi: 10.1089/dia.2017.0054. Epub 2017 May 22. Review.

36.

Impact on Diabetes Self-Management and Glycemic Control of a New Color-Based SMBG Meter.

Schnell O, Klausmann G, Gutschek B, Garcia-Verdugo RM, Hummel M.

J Diabetes Sci Technol. 2017 Nov;11(6):1218-1225. doi: 10.1177/1932296817706376. Epub 2017 Apr 26.

37.

The integrative metabolomic-transcriptomic landscape of glioblastome multiforme.

Heiland DH, Wörner J, Gerrit Haaker J, Delev D, Pompe N, Mercas B, Franco P, Gäbelein A, Heynckes S, Pfeifer D, Weber S, Mader I, Schnell O.

Oncotarget. 2017 Jul 25;8(30):49178-49190. doi: 10.18632/oncotarget.16544.

38.

Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group.

Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, Valensi P, Rahelic D, Ceriello A.

Cardiovasc Diabetol. 2017 Mar 11;16(1):35. doi: 10.1186/s12933-017-0508-8. Erratum in: Cardiovasc Diabetol. 2017 Oct 18;16(1):135.

39.

Comprehensive analysis of PD-L1 expression in glioblastoma multiforme.

Heiland DH, Haaker G, Delev D, Mercas B, Masalha W, Heynckes S, Gäbelein A, Pfeifer D, Carro MS, Weyerbrock A, Prinz M, Schnell O.

Oncotarget. 2017 Jun 27;8(26):42214-42225. doi: 10.18632/oncotarget.15031.

40.

Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes.

Standl E, Schnell O, McGuire DK, Ceriello A, Rydén L.

Lancet Diabetes Endocrinol. 2017 May;5(5):391-402. doi: 10.1016/S2213-8587(17)30033-5. Epub 2017 Jan 26. Review. Erratum in: Lancet Diabetes Endocrinol. 2017 May;5(5):e3.

PMID:
28131656
41.

Time-saving screening for diabetes in patients with coronary artery disease: a report from EUROASPIRE IV.

Gyberg V, De Bacquer D, Kotseva K, De Backer G, Schnell O, Tuomilehto J, Wood D, Rydén L.

BMJ Open. 2016 Dec 8;6(12):e013835. doi: 10.1136/bmjopen-2016-013835.

42.

Impact of HbA1c Testing at Point of Care on Diabetes Management.

Schnell O, Crocker JB, Weng J.

J Diabetes Sci Technol. 2017 May;11(3):611-617. doi: 10.1177/1932296816678263. Epub 2016 Nov 27. Review.

43.

Current perspectives on cardiovascular outcome trials in diabetes.

Schnell O, Rydén L, Standl E, Ceriello A; D&CVD EASD Study Group.

Cardiovasc Diabetol. 2016 Oct 1;15(1):139. Review.

44.

Need for Outcome Scenario Analysis of Clinical Trials in Diabetes.

Garcia-Verdugo R, Erbach M, Schnell O.

J Diabetes Sci Technol. 2017 Mar;11(2):327-334. doi: 10.1177/1932296816670925. Epub 2016 Oct 5.

45.

Molecular differences between cerebral blood volume and vessel size in glioblastoma multiforme.

Heiland DH, Demerath T, Kellner E, Kiselev VG, Pfeifer D, Schnell O, Staszewski O, Urbach H, Weyerbrock A, Mader I.

Oncotarget. 2017 Feb 14;8(7):11083-11093. doi: 10.18632/oncotarget.11522.

46.

Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.

Schnell O, Thorsteinsdottir J, Fleischmann DF, Lenski M, Abenhardt W, Giese A, Tonn JC, Belka C, Kreth FW, Niyazi M.

J Neurooncol. 2016 Dec;130(3):591-599. Epub 2016 Sep 6.

PMID:
27599828
47.

Oral glucose tolerance testing and cardiovascular disease.

Rydén L, Viveca G, Schnell O, Jaakko T; EUROASPIRE IV investigators.

Lancet Diabetes Endocrinol. 2016 Sep;4(9):732-733. doi: 10.1016/S2213-8587(16)30183-8. No abstract available.

PMID:
27542923
48.

Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.

Standl E, Schnell O, McGuire DK.

Circ Res. 2016 May 27;118(11):1830-43. doi: 10.1161/CIRCRESAHA.116.306924. Review.

PMID:
27230644
49.

Chemotherapy for intracranial ependymoma in adults.

Gramatzki D, Roth P, Felsberg J, Hofer S, Rushing EJ, Hentschel B, Westphal M, Krex D, Simon M, Schnell O, Wick W, Reifenberger G, Weller M.

BMC Cancer. 2016 Apr 23;16:287. doi: 10.1186/s12885-016-2323-0.

50.

Interferences and Limitations in Blood Glucose Self-Testing: An Overview of the Current Knowledge.

Erbach M, Freckmann G, Hinzmann R, Kulzer B, Ziegler R, Heinemann L, Schnell O.

J Diabetes Sci Technol. 2016 Aug 22;10(5):1161-8. doi: 10.1177/1932296816641433. Print 2016 Sep. Review.

Supplemental Content

Loading ...
Support Center